SRRK Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of 16.99%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Scholar Rock Holding Corp. has a consensus price target of $50.36, signalling upside risk potential of 13.75%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Scholar Rock Holding Corp..

Scholar Rock Holding Corp. has a beta of 0.671, which suggesting that the stock is 32.859% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of 47.99%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

Scholar Rock Holding Corp. has a consensus price target of $50.36, signalling upside risk potential of 13.75%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $313.22 which suggests that it could grow by 13.64%. Given that Scholar Rock Holding Corp. has higher upside potential than Krystal Biotech, Inc., analysts believe Scholar Rock Holding Corp. is more attractive than Krystal Biotech, Inc..

Scholar Rock Holding Corp. has a beta of 0.671, which suggesting that the stock is 32.859% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than Krystal Biotech, Inc. quarterly revenues of $107.1M. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 40.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 21.20x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of -360.68%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Scholar Rock Holding Corp. has a consensus price target of $50.36, signalling upside risk potential of 13.75%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $41.70 which suggests that it could grow by 14.53%. Given that Stoke Therapeutics, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Stoke Therapeutics, Inc. is more attractive than Scholar Rock Holding Corp..

Scholar Rock Holding Corp. has a beta of 0.671, which suggesting that the stock is 32.859% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.101, suggesting its more volatile than the S&P 500 by 10.054%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 55.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 10.33x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks, Inc. has a net margin of -- compared to Scholar Rock Holding Corp.'s net margin of -70.99%. Scholar Rock Holding Corp.'s return on equity of -142.69% beat Zymeworks, Inc.'s return on equity of -18.82%.

Scholar Rock Holding Corp. has a consensus price target of $50.36, signalling upside risk potential of 13.75%. On the other hand Zymeworks, Inc. has an analysts' consensus of $36.46 which suggests that it could grow by 56.56%. Given that Zymeworks, Inc. has higher upside potential than Scholar Rock Holding Corp., analysts believe Zymeworks, Inc. is more attractive than Scholar Rock Holding Corp..

Scholar Rock Holding Corp. has a beta of 0.671, which suggesting that the stock is 32.859% less volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.245, suggesting its more volatile than the S&P 500 by 24.531%.

Scholar Rock Holding Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding Corp. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.

Scholar Rock Holding Corp. quarterly revenues are --, which are smaller than Zymeworks, Inc. quarterly revenues of $27.6M. Scholar Rock Holding Corp.'s net income of -$102.2M is lower than Zymeworks, Inc.'s net income of -$19.6M. Notably, Scholar Rock Holding Corp.'s price-to-earnings ratio is -- while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding Corp. is 72.82x versus 13.12x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.